- Fellowship - UT Southwestern Medical Center (2010-2014), Gastroenterology
- Residency - Massachusetts General Hospital (2007-2010), Internal Medicine
- Medical School - UT Southwestern Medical School (2000-2007)
Luke Engelking, M.D., Ph.D.
- Internal Medicine - Digestive & Liver Diseases
Dr. Engelking is originally from Houston, Texas and first came to UT Southwestern for joint MD/PhD training (2000-2007), where he studied cholesterol and fat metabolism under the tutelage of Nobel Laureates Goldstein and Brown. He then completed his clinical training in internal medicine at Massachusetts General Hospital (2007-2010), an affiliate of Harvard Medical School. Drawn by the opportunity to study lipid metabolism in the intestine, he returned to UT Southwestern for a fellowship in gastroenterology and hepatology (2010-2014) and thereafter joined the faculty of the Departments of Internal Medicine (Division of Digestive and Liver Diseases) and Molecular Genetics. His current research interests include understanding the role of the intestine in the control of metabolism, particularly focused on the intestine’s contribution to lipid-related disorders such as obesity, fatty liver disease, and hyperlipidemia.
- American Gastroenterological Association (2010), Member
- American College of Gastroenterology (2014), Member
- University Honors 2000, Texas A&M University
- Alpha Omega Alpha 2007, Honor Medical Society
- Distinguished Researcher's Award 2014, UT Southwestern President's Research Council
Identification of BV/ODV-C42, an Autographa californica nucleopolyhedrovirus orf101-encoded structural protein detected in infected-cell complexes with ODV-EC27 and p78/83.
Braunagel SC, Guidry PA, Rosas-Acosta G, Engelking L, Summers MD Journal of virology 2001 Dec 75 24 12331-8
Severe facial clefting in Insig-deficient mouse embryos caused by sterol accumulation and reversed by lovastatin.
Engelking LJ, Evers BM, Richardson JA, Goldstein JL, Brown MS, Liang G The Journal of clinical investigation 2006 Sep 116 9 2356-65
Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis.
Engelking LJ, Kuriyama H, Hammer RE, Horton JD, Brown MS, Goldstein JL, Liang G The Journal of clinical investigation 2004 Apr 113 8 1168-75
Schoenheimer effect explained--feedback regulation of cholesterol synthesis in mice mediated by Insig proteins.
Engelking LJ, Liang G, Hammer RE, Takaishi K, Kuriyama H, Evers BM, Li WP, Horton JD, Goldstein JL, Brown MS The Journal of clinical investigation 2005 Sep 115 9 2489-98
Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine.
McFarlane MR, Liang G, Engelking LJ The Journal of biological chemistry 2014 Jan 289 4 2148-56
Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes.
Engelking LJ, McFarlane MR, Li CK, Liang G Journal of lipid research 2012 Jul 53 7 1359-68
Compensatory increase in fatty acid synthesis in adipose tissue of mice with conditional deficiency of SCAP in liver.
Kuriyama H, Liang G, Engelking LJ, Horton JD, Goldstein JL, Brown MS Cell metabolism 2005 Jan 1 1 41-51
- Identification of BV/ODV-C42, an Autographa californica nucleopolyhedrovirus orf101-encoded structural protein detected in infected-cell complexes with ODV-EC27 and p78/83.
- SREBP, Scap and Insig Proteins
- Enteroendocrine Cell Biology
- Cholesterol and Fat Metabolism